Actualités 17 avr 2024 Addex Therapeutics lance la spin-off Neurosterix à Genève avec un investissement de USD 63 millions La société genevoise Addex Therapeutics s’est associée à Perceptive Advisors pour lancer la spin-off Neurosterix, un nouvel acteur dans le dévelo...
News 17 avr 2024 Addex Therapeutics launches spin-off Neurosterix in Geneva with USD 63 million investment Geneva's Addex Therapeutics has teamed up with Perceptive Advisors to launch spin-off Neurosterix, a new player in neurology-focused drug develop...
Aktuell 20 oct 2023 Xlife Sciences wird Hauptaktionär von 4D Lifetec Xlife Sciences, ein börsennotierter Beschleuniger und Investor für innovative Gesundheitslösungen, beteiligt sich mit 23,3 Millionen Franken an d...
Aktuell 26 mar 2024 Zürcher Forschende machen Krebstherapie wieder wirksam Forschende der Universität Zürich und des Universitätsspitals Zürich haben herausgefunden, wie mutierte Blutkrebszellen wieder auf eine Immunther...
News 20 oct 2023 Xlife Sciences becomes main shareholder in 4D Lifetec Xlife Sciences, a listed accelerator and investor in innovative healthcare solutions, has made an investment totalling 23.3 million Swiss francs ...
Aktuell 13 mar 2024 PSI entwickelt neue Krebstherapie Forschende des Paul Scherrer Instituts (PSI) haben ein Radiopharmakon gegen metastasierende neuroendokrine Tumore entwickelt. Mit der erstmaligen...
News 18 oct 2023 BioArk Monthey’s third building signifies exponential growth in the life sciences sector With two decades under its belt, the BioArk site in Monthey continues to cement its position as a front-runner in life sciences.
News 26 mar 2024 Zurich researchers make cancer therapy effective again Researchers from the University of Zurich and University Hospital Zurich have discovered how mutated blood cancer cells can be made to respond to...
News 10 jan 2024 The remarkable chemical-pharmaceutical industry in the canton of Valais For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation ...
News 13 mar 2024 PSI developing new cancer therapy Researchers from the Paul Scherrer Institute (PSI) have developed a radiopharmaceutical to combat metastatic neuroendocrine tumors. After having ...
News 22 déc 2023 Zynnon hits milestone in the diagnosis of respiratory infections Zynnon has reached a milestone with its technology for diagnosing viral respiratory infections. Following successful studies in hospitals, the co...
News 14 aoû 2023 Bern’s thriving ecosystem for life sciences innovation In the heart of Western Switzerland, the canton of Bern has emerged as a location of choice for companies in the life sciences sector.
News 07 aoû 2023 Longevity start-up EPITERNA raises EUR 10 million to slow ageing and extend lifespan Vaud-based longevity start-up EPITERNA has secured EUR 10 million in funding from Prima Materia, an investment firm founded by Spotify founder Da...
News 23 oct 2023 Valsynthèse, 40 years of innovation in the canton of Valais From dynamite to pharmaceuticals, Valsynthèse, the 'fine chemistry' business unit of the Société Suisse des Explosifs, celebrates four decades of...
News 27 oct 2023 UZH researchers develop method for transport of large genes Researchers at the University of Zurich (UZH) have developed a new method for transporting large genes, enabling them to be transferred efficient...
最新 25 déc 2023 瑞士初创公司 Zynnon在呼吸道感染的诊断方面实现突破 Zynnon在诊断病毒性呼吸道感染的技术上实现突破。在医院成功研究后,这家来自大苏黎世地区的公司已开始生产原型。随后还将进行进一步的临床试验。
News 26 mai 2023 UCB: "It's difficult to beat Swiss quality - even the Chinese admit as much." UCB UCB is a global biopharmaceutical company based in Belgium. Since 1996, it has invested more than 600 million Swiss francs in a state-of-the-art ...
News 18 oct 2023 Cimeio collaborating with the University of Pennsylvania The Basel-based start-up Cimeio has been offered an exceptional opportunity for a preclinical research collaboration with the University of Penns...